A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary

Recruiting

99 years or below

All

Phase 1

5 participants needed

1 Location

Brief description of study

To evaluate the safety and tolerability of STRO-002/bevacizumab as a combination therapy. To further evaluate the toxicity and tolerability of STRO-002/bevacizumab in patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) To characterize the PK of STRO-002 when administered with bevacizumab To assess the immunogenic potential of STRO-002 when administered with bevacizumab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 10 May 2023. Study ID: 850700

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor alpha (FolR) Antibody Drug Conjugate (ADC) in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Brief description of study

Eligibility of study

Find a site

Interested in the study